Annovis Bio Inc. (NYSE: ANVS) will present new data on Buntanetap, its investigational drug for Alzheimer's disease (AD), at the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, from October 29 to November 1, 2024. The presentations will focus on the efficacy of Buntanetap in early AD patients and its effects on key biomarkers associated with neurodegeneration.
Presentations at CTAD 2024
Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present two scientific posters:
- Poster LP023: "Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients." This poster will be presented on Tuesday, October 29, and Wednesday, October 30 (CET).
- Poster LP074: "Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer’s Clinical Studies." This poster will be presented on Thursday, October 31 (CET).
The posters will be available on Annovis’ website following the conclusion of the conference.
About Buntanetap
Buntanetap is a late-stage clinical drug platform being developed by Annovis Bio to treat neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. The drug is designed to target multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
Significance of CTAD
The CTAD conference is a key event for the Alzheimer’s research community, bringing together pharmaceutical companies, academic research centers, and patient advocacy groups to discuss innovative treatments for Alzheimer’s disease. Annovis Bio's presentations at CTAD 2024 are expected to provide valuable insights into the potential of Buntanetap as a novel therapeutic approach for AD.
